While the drug combo did meet the first goal of increasing progression-free survival, it failed to prolong overall survival beyond what is normal for patients on chemotherapy without Erbitux.
But staff have remained worried about some of the changes, which are being looked at which include increasing working hours, cutting holiday entitlement and sick pay, and performance related pay progression.